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The present study was designed to evaluate the effect of bovine immunodeficiency virus (BIV) infection on
immune functions and possible interactions between BIV and other bovine viruses in calves. Ten calves were
inoculated intravenously with BIV, and five served as controls. An increased lymphocyte proliferation to BIV
gag protein was demonstrated 2 to 6 weeks after BIV inoculation (P < 0.05). Lymphocyte subset differentiation
revealed a decreased CD4/CD8 ratio (P < 0.05) during weeks 2 to 7, suggesting a possible immune dysfunction
in BIV-infected calves. When the calves were inoculated with bovine herpesvirus type 1 (BHV-1), the antibody
response to BHV-1 in BIV-infected calves was delayed and the antibody titers were significantly lower (P <
0.05). Injection of bovine viral diarrhea virus vaccine also elicited a lower neutralizing antibody response in
BIV-infected calves. The results indicated that immune suppression occurred in BIV-infected calves.
Bovine immunodeficiency virus (BIV), a lentivirus of the
family Retroviridae, was first isolated from a dairy cow with
lymphocytosis, lymphadenopathy, neuropathy, and progressive
emaciation (19). Studies have shown that BIV resembles hu-
man immunodeficiency virus and other lentiviruses, e.g.,
equine infectious anemia virus, in its structural, genetic, anti-
genic, and biological properties (1, 3, 9). Recent serological
surveys have shown that BIV infection is worldwide, with the
highest incidence being one of up to 60% of herd population in
South America (6, 8, 11, 13, 18, 21). Although clinical disease
has not been reproduced reliably by BIV experimental inocu-
lation in cattle, BIV infections have been established success-
fully in cattle and other species, as shown by detectable antibody
and the presence of virus in peripheral blood mononuclear cells
(PBMC) (4, 7, 12, 20, 21).
The immunological effect of BIV infection in cattle has been
studied by several research groups (7, 12, 14). However, the
experiments were often based on a limited number of animals
and the results were sometime inconsistent with each other. In
one study, an increase in lymphocyte proliferation to phytohe-
magglutinin (PHA) was demonstrated in calves 4 months after
infection (7), while in another investigation, an association of
BIV infection with decreased lymphocyte proliferation to
pokeweed mitogen and concanavalin A (Con A) as well as to
PHA was found in calves 6 months after infection (12). A
depletion of CD41 cells in two experimentally infected calves
3 to 4 months after inoculation with the original BIV strain,
R-29, was reported (17). It was also noted that there was a
delay in the humoral immune response against foreign proteins
in three BIV-infected calves (10, 14). In this study, fifteen
calves were used in the experiment in order to further evaluate
the immune functions of BIV-infected calves and to investigate
the effect of BIV infection on the immune responses to other
important bovine viruses, e.g., bovine herpesvirus type 1
(BIV-1) and bovine viral diarrhea virus (BVDV).
Fifteen calves 8 to 9 months old were selected for the ex-
periment, and they were free of antibodies to bovine leukemia
virus, BVDV, BHV-1, and BIV. The calves were housed in the
isolation facilities at the Animal Resource in the College of
Veterinary Medicine, Kansas State University. Ten of the
calves were inoculated intravenously with 50 ml of BIV (isolate
R-29)-infected fetal bovine lung (FBL) cells (105 cells/ml), and
five calves inoculated with 50 ml of FBL cells (105 cells/ml)
served as controls. To evaluate the effect of BIV infection on
the immune responses to other bovine viruses, five BIV-in-
fected and five non-BIV-infected calves were inoculated intra-
nasally with BHV-1 (Cooper strain; 2 3 106 PFU/calf) 24
weeks after BIV infection and the other five BIV-infected
calves served as controls. Forty-two weeks after BIV injection,
four BIV-infected and two non-BIV-infected calves were given
intramuscularly a single dose of BVDV vaccine (Sanofi Animal
Health Inc., Lenexa, Kans.). For immune function analysis and
virus detection in calves, blood samples were collected and
rectal temperature and clinical observations were recorded
twice a week during weeks 0 to 8 after each treatment, i.e., BIV
and BHV-1 inoculations and BVDV vaccine injection, and
once a week after 8 weeks of each treatment. Nasal swabs were
taken twice a week after BHV-1 inoculation for BHV-1 isola-
tion.
For immune function assays, blood samples were collected
from the jugular vein in Vacutainer tubes containing sodium
heparin (Becton Dickinson, Rutherford, N.J.). Buffy coat con-
taining PBMC was isolated by the density gradient method as
described by Roth et al. (16). Mononuclear cells were finally
resuspended in Dulbecco’s modified Eagle medium enriched
with 10% fetal bovine serum (FBS), nonessential amino acids,
vitamins, and sodium pyruvate (Life Technologies, Gaithers-
burg, Md.) at a concentration of 2 3 106 cells/ml. The lym-
phocyte proliferation assay was performed by a procedure
adapted from those previously described by Clerici et al. (5).
PBMC (2 3 105) were dispensed into each well of 96-well
tissue culture plates (Becton Dickinson) along with four rep-
licates of each mitogen, antigen, and control medium. In the
preliminary study, the optimal final concentrations of mitogens
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and antigens were determined to be the following: 10 mg/ml for
PHA (Murex Diagnostics Ltd., Hartford, England), 5 mg/ml for
Con A (Sigma Chemical Co., St. Louis, Mo.), 60 mg/ml for
lipopolysaccharide (Sigma Chemical Co.), 1 mg/ml for BIV
recombinant gag protein and Escherichia coli fusion protein
(2), and 5 3 106 50% tissue culture infective doses
(TCID50)/ml for BHV-1 and BVDV inactivated viral antigens.
Undiluted BIV-FBL cell culture supernatant also was included
in the assay as a control stimulator. After mitogens and anti-
gens were added, the plates were incubated at 378C for 72 h
with 5% CO2 in a humidified incubator, followed by an 18-h
incubation with 1 mCi of [3H]thymidine (specific activity, 6.7
Ci/mmol; NEN, Boston, Mass.) in each well. The cells were
collected by a PHD cell harvester (Cambridge Technology
Inc., Cambridge, Mass.), and tritium incorporation in the cells
was measured by a scintillation counter (Pharmacia/LKB,
Uppsala, Sweden). The results were calculated as a stimulation
index (SI), in which the mean values for disintegrations per
minute (DPM) from four replicate wells of PBMC with mito-
gens or antigens were divided by the mean DPM values from
four replicate wells of PBMC in the control medium.
In lymphocyte subset analysis, PBMC (106 cells) suspended
in each tube were washed twice with phosphate-buffered saline
(PBS; 0.01 M, pH 7.2) by centrifugation at 2,000 3 g for 4 min.
Then, 150 ml (2 mg) of the appropriate primary monoclonal
antibodies, including anti-bovine CD4, anti-bovine CD8, and
anti-bovine immunoglobulin M (IgM; VMRD, Pullman, Wash.),
was added to the cells in each tube. After incubation at 48C for
30 min, the cells were washed three times with cold PBS. A
second 30-min incubation at 48C was performed in 150 ml of
fluorescein isothiocyanate-conjugated goat anti-mouse IgG-
IgM antibody (HyClone Laboratories, Inc., Logan, Utah) di-
luted 1:100. The cells were washed three more times and fixed
in 0.5 ml of PBS containing 0.2% paraformadehyde. The fixed
cells were stored at 48C in the dark until analyzed; analysis was
performed within a week. Flow cytometric analysis of CD4,
CD8, and B cells was performed by counting 10,000 cells from
each sample on the FACscan flow cytometer (Becton Dickin-
son).
Detection of BIV antibody by Western blot analysis with
recombinant gag protein as antigen was performed as de-
scribed by Atkinson et al. (2). Virus isolation was performed by
cocultivation of PBMC with FBL cells as previously described
(21, 22). BIV infection was further confirmed by amplification
of a conserved BIV pol gene segment from PBMC genomic
DNA by PCR with a pair of designed primers (BIV 127, nu-
cleotides [nt] 2257 to 2275, ATGCTAATGGATTTTAGGGA;
and BIV 127, nt 2478 to 2497, CATCCTTGTGGTAGAACA
TT). Thermal cycling was performed in a Perkin-Elmer ma-
chine by completing 35 cycles with the following profile: 958C
for 1 min, 508C for 1 min, and 728C for 2 min. The PCR
products were analyzed on a 1% agarose gel and were con-
firmed by Southern hybridization.
BHV-1- and BVDV-neutralizing antibodies were detected
by a virus neutralization test described by Xue et al. (23). The
50% endpoint of plaque reduction was calculated by the Reed-
Munch method (15). For BHV-1 isolation, nasal swabs taken
from calves were dipped into Dulbecco’s medium containing
10% FBS and antibiotics. The TCID50 test was performed in
flat-bottom 96-well tissue culture plates as previously described
(15). Briefly, the swab-washed media constituting the viral
samples were serially diluted 10-fold with Dulbecco’s medium
containing 5% FBS, and then 100 ml of each dilution was
added to each of four replicate wells of a 96-well plate; this was
followed by the addition of 100 ml of Madin-Darby bovine
kidney cells (1.5 3 105 cells/ml) to each well. The plates were
incubated at 378C with 5% CO2 for 3 days. Cytopathic effect
was checked daily under a microscope, and TCID50 was deter-
mined by the Karber Formula (15).
Experimental data was analyzed by using a t test for the
independent samples. Differences of mean values between the
treated and untreated groups in a particular time interval were
evaluated. These differences were considered significant if P
was ,0.05.
Three weeks after BIV inoculation, all of the 10 BIV-inoc-
ulated calves developed antibodies specific to BIV gag protein,
as detected by Western blot analysis, and the antibodies were
detected in the calves throughout the experiment. No BIV-
positive seroconversion occurred in non-BIV-infected calves.
BIV could be reisolated from PBMC from the BIV-infected
calves at 3 weeks postinfection (p.i.) and thereafter, but not
from PBMC from control calves. PCR analysis further con-
firmed BIV infection in BIV-inoculated calves (data not
shown). The results showed that BIV infection was established
successfully in calves.
During the period of BIV infection, all calves remained
clinically normal. After BHV-1 inoculation, typical symptoms
of BHV-1 infection were observed in all the BHV-1-inoculated
calves but not in control calves, and the symptoms disappeared
within 2 weeks of BHV-1 inoculation. No abnormal clinical
signs were observed after BVDV vaccine inoculation in both
BIV-infected and uninfected calves. No significant hematolog-
ical change was found in any of the calves during the BIV
infection and other treatments.
An increased specific lymphocyte proliferation to BIV anti-
gens, but not to mitogens and to BHV-1 and BVDV viral
antigens, was demonstrated in BIV-infected calves. The SI for
purified recombinant BIV gag protein was significantly higher
for the BIV-infected calves than for control calves for 2 to 7
weeks p.i. (P , 0.05) (Fig. 1). After 7 weeks, BIV-infected
calves still tended to have a relatively high SI compared with
control calves, but the difference was not statistically signifi-
cant. The proliferation response to BIV-infected FBL cell cul-
ture supernatant in BIV-infected calves also tended to be
higher than that in the non-BIV-infected ones during weeks 3
to 6, although this difference was not statistically significant.
Lymphocyte proliferation to PHA, Con A, lipopolysaccharide,
BHV-1, and BVDV antigens and to E. coli fusion protein was
unchanged after BIV infection (data not shown).
For BIV-infected calves, a temporary but significant drop in
FIG. 1. Lymphocyte proliferation in BIV-infected (n 5 10) and control (n 5
5) calves stimulated by recombinant BIV gag protein. Data are mean SIs 6
standard errors of the means.
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the CD4/CD8 ratio compared to that for control calves was
observed during weeks 3 to 7 after BIV inoculation. The CD4/
CD8 ratio change, shown in Fig. 2, was due to the decrease in
CD41 cells and the increase in CD81 cells. For the BIV-
infected calves, the mean value of the CD4/CD8 ratio dropped
to 1.34 in week 4 p.i., whereas for the control calves, the mean
value of the CD4/CD8 ratio was 2.0. After 8 weeks, the CD4/
CD8 ratio for BIV-infected and control calves became the
same.
Figure 3 shows the responses of neutralizing antibody to
BHV-1 in BIV-infected and non-BIV-infected calves after
BHV-1 inoculation. In the non-BIV-infected group, neutraliz-
ing antibody production started on day 7 after BHV-1 inocu-
lation and the average antibody titer during the period from 11
to 35 days after BHV-1 infection was 1:70, while in the BIV-
infected group, neutralizing antibody production started on
day 11 and the average antibody titer was only 1:30. A similar
result was found for the calves inoculated with BVDV vaccine.
The BIV-infected calves tended to have lower neutralizing
antibody titers to BVDV vaccination (Fig. 4) than the non-
BIV-infected calves.
BHV-1 could be recovered immediately after BHV-1 intra-
nasal inoculation, and virus titer in the nasal cavity peaked at
106 TCID50/ml within a week. The virus disappeared on day 12
after BHV-1 inoculation for both the BIV-infected and non-
BIV-infected groups.
In the experiment, the SI of lymphocyte proliferation to BIV
recombinant gag protein was significantly higher for the in-
fected calves than for the control calves (P , 0.05) and the SI
to the BIV-FBL cell culture supernatant also tended to be
higher for infected animals. However, it was also noted that the
SI of recombinant gag protein for control calves was somewhat
elevated during the first 7 weeks of BIV infection (Fig. 1). It is
most likely that the calves exposed to the E. coli proteins in the
environment before or during the BIV infection could activate
the immune system. When BIV recombinant gag protein, con-
taining a portion of E. coli fusion protein, was used as antigen,
it specifically stimulated lymphocyte proliferation to both BIV
gag and E. coli fusion proteins. The conclusion concerning
immune system activation was supported by the observation
that lymphocytes from both BIV-infected and control calves
were stimulated by E. coli fusion protein but not by other viral
proteins.
A significant decrease in CD4/CD8 ratio during weeks 3 to
7 after BIV inoculation suggests a possible immune dysfunc-
tion because of the depletion of the CD41 T-cell population by
BIV infection. Although there was no direct evidence to show
how BIV could act on CD41 T cells, the coincidence in the
timing of the decrease in CD41 T-cell number and the rapid
replication of BIV indicated a possible interaction between
BIV and CD41 T cells (14). BIV-infected calves gave delayed
and significantly lower neutralizing antibody responses when
they were inoculated with BHV-1 6 months after BIV infec-
tion. Antibody titers to BVDV were also lower in the BIV-
infected calves compared with controls after BVDV vaccine
injection. Reduction and delay in the antibody responses to the
two viruses observed in the BIV-infected calves may possibly
be due to viral interference or immune competition among
them. Other studies have also found a decrease in immune
response to foreign proteins in BIV-infected calves. It was also
found that this delay of immune response could be prevented
by injecting serum thymic factor into BIV-infected calves (10),
strongly indicating that the dysfunction in antibody response
related to immune suppression occurred in BIV-infected calves.
FIG. 2. CD4/CD8 ratios for BIV-infected (n 5 10) and control (n 5 5)
calves. CD41 and CD81 cell numbers were determined by counting 10,000 cells
by flow cytometry. Data are mean values of the CD4/CD8 ratio6 standard errors
of the means.
FIG. 3. Production of neutralizing antibody to BHV-1 in BIV-infected (E;
n 5 5) and non-BIV-infected (; n 5 5) calves after BHV-1 inoculation. BIV-
infected calves without BHV-1 inoculation (h; n 5 5) served as controls. Data
are mean antibody titers 6 standard errors of the means.
FIG. 4. Production of neutralizing antibody to BVDV in BIV-infected (};
n 5 4) and non-BIV-infected (; n 5 2) infected calves after BVDV vaccine
injection. Data are mean antibody titers 6 standard errors of the means.
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